Literature DB >> 18546617

Epigenetic markers of ovarian cancer.

Caroline A Barton1, Susan J Clark, Neville F Hacker, Philippa M O'Brien.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18546617     DOI： 10.1007/978-0-387-68969-2_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  7 in total

1.  The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.

Authors:  Fang Fang; Joanne Munck; Jessica Tang; Pietro Taverna; Yinu Wang; David F B Miller; Jay Pilrose; Gavin Choy; Mohammad Azab; Katherine S Pawelczak; Pamela VanderVere-Carozza; Michael Wagner; John Lyons; Daniela Matei; John J Turchi; Kenneth P Nephew
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

2.  Increased DNA methyltransferase activity and DNA methylation following Epidermal Growth Factor stimulation in ovarian cancer cells.

Authors:  Sabrina L Samudio-Ruiz; Laurie G Hudson
Journal:  Epigenetics       Date:  2012-03       Impact factor: 4.528

3.  Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.

Authors:  Fang Fang; Horacio Cardenas; Hao Huang; Guanglong Jiang; Susan M Perkins; Chi Zhang; Harold N Keer; Yunlong Liu; Kenneth P Nephew; Daniela Matei
Journal:  Cancer Res       Date:  2017-12-11       Impact factor: 12.701

4.  A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.

Authors:  Daniela Matei; Sharad Ghamande; Lynda Roman; Angeles Alvarez Secord; John Nemunaitis; Merry Jennifer Markham; Kenneth P Nephew; Simone Jueliger; Aram Oganesian; Sue Naim; Xiang Yao Su; Harold Keer; Mohammad Azab; Gini F Fleming
Journal:  Clin Cancer Res       Date:  2018-03-02       Impact factor: 12.531

5.  A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

Authors:  Amit M Oza; Ursula A Matulonis; Angeles Alvarez Secord; John Nemunaitis; Lynda D Roman; Sarah P Blagden; Susana Banerjee; William P McGuire; Sharad Ghamande; Michael J Birrer; Gini F Fleming; Merry Jennifer Markham; Hal W Hirte; Diane M Provencher; Bristi Basu; Rebecca Kristeleit; Deborah K Armstrong; Benjamin Schwartz; Patricia Braly; Geoff D Hall; Kenneth P Nephew; Simone Jueliger; Aram Oganesian; Sue Naim; Yong Hao; Harold Keer; Mohammad Azab; Daniela Matei
Journal:  Clin Cancer Res       Date:  2019-12-12       Impact factor: 12.531

6.  Potential markers for detection and monitoring of ovarian cancer.

Authors:  Brandon J D Rein; Sajal Gupta; Rima Dada; Joelle Safi; Chad Michener; Ashok Agarwal
Journal:  J Oncol       Date:  2011-04-11       Impact factor: 4.375

7.  The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers.

Authors:  Kyung-Jin Min; Kyeong A So; Yung-Taek Ouh; Jin-Hwa Hong; Jae-Kwan Lee
Journal:  J Ovarian Res       Date:  2012-10-15       Impact factor: 4.234
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.